Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LEXICON PHARMACEUTICALS, INC. Director's Dealing 2013

Feb 4, 2013

32814_dirs_2013-02-04_1bff3420-92ba-465e-8045-d2b01ec37606.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC./DE (LXRX)
CIK: 0001062822
Period of Report: 2013-01-31

Reporting Person: Tessmer James F (VP, Finance & Accounting)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-01-31 Common Stock M 13200 Acquired 41870 Direct
2013-01-31 Common Stock F 4310 $2.11 Disposed 37560 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-01-31 Restricted Stock Units (Phantom Stock) $ M 13200 Disposed Common Stock (13200) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

F3: Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent.